MACROGENICS, INC. (NASDAQ:MGNX) Files An 8-K Other Events
Item 8.01. Other Events
On February 6, 2019, the Company issued a press release announcing top-line results from its Phase 3 SOPHIA trial. SOPHIA is a randomized, controlled, multi-center study that compares margetuximab plus chemotherapy to trastuzumab plus chemotherapy in subjects with metastatic breast cancer. A copy of the press release (“the Press Release”) is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
MACROGENICS INC Exhibit
EX-99.1 2 sophiatoplineresults2019pr.htm EXHIBIT 99.1 Exhibit MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab•Margetuximab improved progression-free survival (PFS) compared to HERCEPTIN® (trastuzumab),…
To view the full exhibit click here
About MACROGENICS, INC. (NASDAQ:MGNX)
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.
